Table of Contents

1 Market Overview

• 1.1 Durvalumab Introduction
• 1.2 Market Analysis by Type
  • 1.2.1 2.4mL Injection
  • 1.2.2 10mL Injection
• 1.3 Market Analysis by Applications
  • 1.3.1 Locally Advanced Urothelial Carcinoma
  • 1.3.2 Metastatic Urothelial Carcinoma
  • 1.3.3 Other
• 1.4 Market Analysis by Regions
  • 1.4.1 North America (United States, Canada and Mexico)
    • 1.4.1.1 United States Market States and Outlook (2014-2024)
    • 1.4.1.2 Canada Market States and Outlook (2014-2024)
    • 1.4.1.3 Mexico Market States and Outlook (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy)
    • 1.4.2.1 Germany Market States and Outlook (2014-2024)
    • 1.4.2.2 France Market States and Outlook (2014-2024)
    • 1.4.2.3 UK Market States and Outlook (2014-2024)
    • 1.4.2.4 Russia Market States and Outlook (2014-2024)
    • 1.4.2.5 Italy Market States and Outlook (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
    • 1.4.3.1 China Market States and Outlook (2014-2024)
    • 1.4.3.2 Japan Market States and Outlook (2014-2024)
    • 1.4.3.3 Korea Market States and Outlook (2014-2024)
    • 1.4.3.4 India Market States and Outlook (2014-2024)
    • 1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
  • 1.4.4 South America, Middle East and Africa
    • 1.4.4.1 Brazil Market States and Outlook (2014-2024)
    • 1.4.4.2 Egypt Market States and Outlook (2014-2024)
    • 1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
    • 1.4.4.4 South Africa Market States and Outlook (2014-2024)
    • 1.4.4.5 Turkey Market States and Outlook (2014-2024)
• 1.5 Market Dynamics
  • 1.5.1 Market Opportunities
  • 1.5.2 Market Risk
  • 1.5.3 Market Driving Force

2 Manufacturers Profiles

• 2.1 Medimmune (AstraZeneca)
  • 2.1.1 Business Overview
  • 2.1.2 Durvalumab Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 Medimmune (AstraZeneca) Durvalumab Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)

3 Global Durvalumab Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)

• 3.1 Global Durvalumab Sales and Market Share by Manufacturer (2017-2018)
• 3.2 Global Durvalumab Revenue and Market Share by Manufacturer (2017-2018)
• 3.3 Market Concentration Rate
  • 3.3.1 Top 3 Durvalumab Manufacturer Market Share in 2018
  • 3.3.2 Top 6 Durvalumab Manufacturer Market Share in 2018
• 3.4 Market Competition Trend

4 Global Durvalumab Market Analysis by Regions

• 4.1 Global Durvalumab Sales, Revenue and Market Share by Regions
  • 4.1.1 Global Durvalumab Sales and Market Share by Regions (2014-2019)
  • 4.1.2 Global Durvalumab Revenue and Market Share by Regions (2014-2019)
• 4.2 North America Durvalumab Sales and Growth Rate (2014-2019)
• 4.3 Europe Durvalumab Sales and Growth Rate (2014-2019)
• 4.4 Asia-Pacific Durvalumab Sales and Growth Rate (2014-2019)
• 4.5 South America Durvalumab Sales and Growth Rate (2014-2019)
• 4.6 Middle East and Africa Durvalumab Sales and Growth Rate (2014-2019)

5 North America Durvalumab by Country

• 5.1 North America Durvalumab Sales, Revenue and Market Share by Country
  • 5.1.1 North America Durvalumab Sales and Market Share by Country (2014-2019)
  • 5.1.2 North America Durvalumab Revenue and Market Share by Country (2014-2019)
• 5.2 United States Durvalumab Sales and Growth Rate (2014-2019)
• 5.3 Canada Durvalumab Sales and Growth Rate (2014-2019)
• 5.4 Mexico Durvalumab Sales and Growth Rate (2014-2019)

6 Europe Durvalumab by Country

• 6.1 Europe Durvalumab Sales, Revenue and Market Share by Country
  • 6.1.1 Europe Durvalumab Sales and Market Share by Country (2014-2019)
  • 6.1.2 Europe Durvalumab Revenue and Market Share by Country (2014-2019)
• 6.2 Germany Durvalumab Sales and Growth Rate (2014-2019)
• 6.3 UK Durvalumab Sales and Growth Rate (2014-2019)
• 6.4 France Durvalumab Sales and Growth Rate (2014-2019)
• 6.5 Russia Durvalumab Sales and Growth Rate (2014-2019)
• 6.6 Italy Durvalumab Sales and Growth Rate (2014-2019)

7 Asia-Pacific Durvalumab by Country

• 7.1 Asia-Pacific Durvalumab Sales, Revenue and Market Share by Country
  • 7.1.1 Asia-Pacific Durvalumab Sales and Market Share by Country (2014-2019)
  • 7.1.2 Asia-Pacific Durvalumab Revenue and Market Share by Country (2014-2019)
• 7.2 China Durvalumab Sales and Growth Rate (2014-2019)
• 7.3 Japan Durvalumab Sales and Growth Rate (2014-2019)
• 7.4 Korea Durvalumab Sales and Growth Rate (2014-2019)
• 7.5 India Durvalumab Sales and Growth Rate (2014-2019)
• 7.6 Southeast Asia Durvalumab Sales and Growth Rate (2014-2019)

8 South America Durvalumab by Country

• 8.1 South America Durvalumab Sales, Revenue and Market Share by Country
  • 8.1.1 South America Durvalumab Sales and Market Share by Country (2014-2019)
  • 8.1.2 South America Durvalumab Revenue and Market Share by Country (2014-2019)
• 8.2 Brazil Durvalumab Sales and Growth Rate (2014-2019)
• 8.3 Argentina Durvalumab Sales and Growth Rate (2014-2019)
• 8.4 Colombia Durvalumab Sales and Growth Rate (2014-2019)

9 Middle East and Africa Durvalumab by Countries

• 9.1 Middle East and Africa Durvalumab Sales, Revenue and Market Share by Country
  • 9.1.1 Middle East and Africa Durvalumab Sales and Market Share by Country (2014-2019)
  • 9.1.2 Middle East and Africa Durvalumab Revenue and Market Share by Country (2014-2019)
• 9.2 Saudi Arabia Durvalumab Sales and Growth Rate (2014-2019)
• 9.3 Turkey Durvalumab Sales and Growth Rate (2014-2019)
• 9.4 Egypt Durvalumab Sales and Growth Rate (2014-2019)
• 9.5 Nigeria Durvalumab Sales and Growth Rate (2014-2019)
• 9.6 South Africa Durvalumab Sales and Growth Rate (2014-2019)

10 Global Durvalumab Market Segment by Type

• 10.1 Global Durvalumab Sales, Revenue and Market Share by Type (2014-2019)
  • 10.1.1 Global Durvalumab Sales and Market Share by Type (2014-2019)
  • 10.1.2 Global Durvalumab Revenue and Market Share by Type (2014-2019)
• 10.2 2.4mL Injection Sales Growth and Price
  • 10.2.1 Global 2.4mL Injection Sales Growth (2014-2019)
  • 10.2.2 Global 2.4mL Injection Price (2014-2019)
• 10.3 10mL Injection Sales Growth and Price
  • 10.3.1 Global 10mL Injection Sales Growth (2014-2019)
  • 10.3.2 Global 10mL Injection Price (2014-2019)

11 Global Durvalumab Market Segment by Application

• 11.1 Global Durvalumab Sales Market Share by Application (2014-2019)
• 11.2 Locally Advanced Urothelial Carcinoma Sales Growth (2014-2019)
• 11.3 Metastatic Urothelial Carcinoma Sales Growth (2014-2019)
• 11.4 Other Sales Growth (2014-2019)

12 Durvalumab Market Forecast (2019-2024)

• 12.1 Global Durvalumab Sales, Revenue and Growth Rate (2019-2024)
• 12.2 Durvalumab Market Forecast by Regions (2019-2024)
  • 12.2.1 North America Durvalumab Market Forecast (2019-2024)
  • 12.2.2 Europe Durvalumab Market Forecast (2019-2024)
  • 12.2.3 Asia-Pacific Durvalumab Market Forecast (2019-2024)
  • 12.2.4 South America Durvalumab Market Forecast (2019-2024)
  • 12.2.5 Middle East and Africa Durvalumab Market Forecast (2019-2024)
• 12.3 Durvalumab Market Forecast by Type (2019-2024)
  • 12.3.1 Global Durvalumab Sales Forecast by Type (2019-2024)
  • 12.3.2 Global Durvalumab Market Share Forecast by Type (2019-2024)
• 12.4 Durvalumab Market Forecast by Application (2019-2024)
  • 12.4.1 Global Durvalumab Sales Forecast by Application (2019-2024)
  • 12.4.2 Global Durvalumab Market Share Forecast by Application (2019-2024)

13 Sales Channel, Distributors, Traders and Dealers

• 13.1 Sales Channel
  • 13.1.1 Direct Marketing
  • 13.1.2 Indirect Marketing
  • 13.1.3 Marketing Channel Future Trend
• 13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

• 15.1 Methodology

Scope of the Report:
The worldwide market for Durvalumab is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Durvalumab in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers
Medimmune (AstraZeneca)

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
2.4mL Injection
10mL Injection

Market Segment by Applications, can be divided into
Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Other

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Durvalumab product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Durvalumab, with price, sales, revenue and global market share of Durvalumab in 2017 and 2018.
Chapter 3, the Durvalumab competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Durvalumab breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Durvalumab market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Durvalumab sales channel, distributors, customers, research findings and conclusion, appendix and data source.